Harleen Bath
Physician Assistant · Washington, DCNPI 1568999316
Payments from drug & device makers
Across 856 payments — averaging $20.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Lilly USA, LLC$1K
- Novartis$1K
- EMD Serono, Inc.$1K
- Lundbeck LLC$1K
- Biogen$947
- plus $8K from 47 others
What the payments were for
- Food & beverage$17,829100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,829 in reported general payments places this provider in the 95th percentile of 372 physician assistant providers in District of Columbia.
See all physician assistant providers in District of Columbia →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UbrelvyUbrogepant | 12 | $40,874 |
| QuliptaAtogepant | 16 | $25,927 |
| Emgality PenGalcanezumab-Gnlm | 19 | $20,942 |
| RytaryCarbidopa/Levodopa | 11 | $15,687 |
| Memantine Hcl ErMemantine Hcl | 23 | $5,168 |
| Rivastigmine | 12 | $4,207 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 64 | $1,928 |
| Gabapentin | 77 | $1,851 |
| Mirtazapine | 66 | $1,625 |
| Memantine Hcl | 42 | $1,585 |
| Eletriptan HbrEletriptan Hydrobromide | 13 | $1,068 |
| Duloxetine Hcl | 34 | $1,025 |
| Donepezil Hcl | 74 | $912 |
| Oxcarbazepine | 12 | $693 |
| Topiramate | 33 | $567 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta | $4,144 | $66,80128 claims |
| Amneal Pharmaceuticals LLCRytary | $420 | $15,68711 claims |
| Upsher-smith Laboratories LLCTopiramate | $40 | $56733 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 372 physician assistant providers in District of Columbia.
Other physician assistant in Washington
- Megan DieterichWashington$413K
- Shana PermanWashington$36K
- Keriann KupermanWashington$24K
- Dustin FronczakWashington$13K
- Irena CulicWashington$13K
- Catherine UgliettaWashington$9K
- Milajurine LindsayWashington$9K
- Joseph HudsonWashington$8K
- Sonia BahrooWashington$7K
- Ryan WierWashington$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.